TITLE

How Often Do You Really Have to See Patients on Warfarin?

AUTHOR(S)
Kuritzky, Louis
PUB. DATE
October 2011
SOURCE
Internal Medicine Alert;10/15/2011 Supplement 2, p151
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information on a study conducted by researcher A. J. Rose on a large population of persons receiving anticoagulation in the U.S.
ACCESSION #
69591485

 

Related Articles

  • How Often Do You Really Have to See Patients on Warfarin? Kuritzky, Louis // OB/GYN Clinical Alert;Nov2011 Clinical Briefs in Primary, p21 

    The article discusses research by A. J. Rose et al, published in a 2011 issue of "Chest" on whether patients might be allowed longer intervals without risking either toxicity of supratherapeutic warfarin dose or thrombotic risk of subtherapeutic levels.

  • Trial stopped after antithrombotic excels in preventing post-angioplasty death, MI.  // Modern Medicine;Jun96, Vol. 64 Issue 6, p14 

    Reports on the performance of abciximab at the clinical trials regarding the safety of its use as an antithrombotic agent. Mechanism of action of the drug; Merits of the drug; Comments from the researchers.

  • Pravastatin: Interaction with oral anticoagulant? Trenque, Thierry; Choisy, Henri // BMJ: British Medical Journal (International Edition);4/6/96, Vol. 312 Issue 7035, p886 

    Presents the case of a 64 year old woman who was diagnosed with atrial fibrillation secondary to an adverse effect caused by the interaction of Pravastatin with an oral anticoagulant. Physiological effect of Pravastatin; Caution in the administration of Pravastatin simultaneous to anticoagulant...

  • Anti-anticoagulation. H.D.B. // Cortlandt Forum;10/25/97, Vol. 10 Issue 10, p108 

    Focuses on the anticoagulant Coumadin that represents an increased risk for complications in an 80-year-old woman with a history of falling. Production of intracranial bleeding due to additional falls while on Coumadin.

  • Wide victory for arteries. Munson, Marty; Higbee, Beth // Prevention;Aug94, Vol. 46 Issue 8, p44 

    Discusses CentroRx, a new clot-blocking drug that may help angioplasty be more effective, and the `first drug ever shown to reduce restenosis and the need for repeat procedures. The drug's lack of some of the side effects in the stomach that aspirin might cause; Risk of bleeding; Other possible...

  • Altering anticoagulation therapy: A survey of physicians.  // Journal of the American Dental Association (JADA);May96, Vol. 127 Issue 5, p666 

    Presents a multiple choice quiz on altering anticoagulation therapy, a survey of physicians. Answers.

  • The new-and improved-anticoagulation regimens. Whieldon, David // Patient Care;12/15/1995, Vol. 29 Issue 20, p31 

    Presents information on anticoagulation regimens. Changes in anticoagulant therapy on the way; What anticoagulation is effective for; Use of heparin for most thromboembolic problems; Candidates for testing for underlying hypercoagulation state; More. INSETS: Whither anticoagulation?.;Heparin...

  • Post-approval adverse events of new and old anticoagulants. Hoffman, Keith B.; Demakas, Andrea; Erdman, Colin B.; Dimbil, Mo // BMJ: British Medical Journal;3/8/2014, Vol. 348 Issue 7948, p23 

    A letter to the editor is presented which discusses the inaccuracy on the general safety of the anticoagulant drug dabigatran.

  • Safety of new anticoagulants in high risk patients. Dalgleish, Stephen // BMJ: British Medical Journal;3/8/2014, Vol. 348 Issue 7948, p23 

    A letter to the editor is presented which discusses the safety of new anticoagulants such as rivaroxaban and dabigatran to high-risk patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics